Cargando…
Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men
INTRODUCTION: Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD-1/PD-L1 in prostate cancer, especially in African men. METHODS:...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098749/ https://www.ncbi.nlm.nih.gov/pubmed/35128628 http://dx.doi.org/10.1007/s40487-022-00184-6 |
_version_ | 1784706446759297024 |
---|---|
author | Katongole, Paul Sande, Obondo J. Reynolds, Steven J. Joloba, Moses Kajumbula, Henry Kalungi, Samuel Ssebambulidde, Kenneth Nakimuli, Cynthia Atuheirwe, Maxine Orem, Jackson Niyonzima, Nixon |
author_facet | Katongole, Paul Sande, Obondo J. Reynolds, Steven J. Joloba, Moses Kajumbula, Henry Kalungi, Samuel Ssebambulidde, Kenneth Nakimuli, Cynthia Atuheirwe, Maxine Orem, Jackson Niyonzima, Nixon |
author_sort | Katongole, Paul |
collection | PubMed |
description | INTRODUCTION: Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD-1/PD-L1 in prostate cancer, especially in African men. METHODS: Plasma concentrations of PD-L1/PD-1 were assessed using enzyme-linked immunosorbent assay in patients with prostate cancer and normal healthy controls at the Uganda Cancer Institute. The associations between plasma PD-L1/PD-1 concentration levels and serum prostate-specific antigen (PSA) levels, Gleason scores, age, and body mass index (BMI) were determined. RESULTS: We found significant differences in the median plasma concentrations of PD-L1 and PD-1 immune checkpoint molecules between prostate cancer cases and normal healthy controls of 0.285 vs 0.035 (p = 0.001) and 0.596 vs 0.355 (p = 0.017), respectively. We found no significant association between age, serum PSA levels, BMI and Gleason scores, and PD-1 among patients with prostate cancer and controls. However, elevated levels of PD-L1 were significantly associated with higher Gleason scores among patients with prostate cancer (p = 0.014). CONCLUSIONS: Elevated PD-L1 levels were statistically significantly linked to high Gleason scores. These results may guide clinicians in assessing the prognosis of patients individually and selecting patients who will be suitable candidates for anti-PD-L1 immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-022-00184-6. |
format | Online Article Text |
id | pubmed-9098749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-90987492022-05-14 Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men Katongole, Paul Sande, Obondo J. Reynolds, Steven J. Joloba, Moses Kajumbula, Henry Kalungi, Samuel Ssebambulidde, Kenneth Nakimuli, Cynthia Atuheirwe, Maxine Orem, Jackson Niyonzima, Nixon Oncol Ther Original Research INTRODUCTION: Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD-1/PD-L1 in prostate cancer, especially in African men. METHODS: Plasma concentrations of PD-L1/PD-1 were assessed using enzyme-linked immunosorbent assay in patients with prostate cancer and normal healthy controls at the Uganda Cancer Institute. The associations between plasma PD-L1/PD-1 concentration levels and serum prostate-specific antigen (PSA) levels, Gleason scores, age, and body mass index (BMI) were determined. RESULTS: We found significant differences in the median plasma concentrations of PD-L1 and PD-1 immune checkpoint molecules between prostate cancer cases and normal healthy controls of 0.285 vs 0.035 (p = 0.001) and 0.596 vs 0.355 (p = 0.017), respectively. We found no significant association between age, serum PSA levels, BMI and Gleason scores, and PD-1 among patients with prostate cancer and controls. However, elevated levels of PD-L1 were significantly associated with higher Gleason scores among patients with prostate cancer (p = 0.014). CONCLUSIONS: Elevated PD-L1 levels were statistically significantly linked to high Gleason scores. These results may guide clinicians in assessing the prognosis of patients individually and selecting patients who will be suitable candidates for anti-PD-L1 immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-022-00184-6. Springer Healthcare 2022-02-07 /pmc/articles/PMC9098749/ /pubmed/35128628 http://dx.doi.org/10.1007/s40487-022-00184-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Katongole, Paul Sande, Obondo J. Reynolds, Steven J. Joloba, Moses Kajumbula, Henry Kalungi, Samuel Ssebambulidde, Kenneth Nakimuli, Cynthia Atuheirwe, Maxine Orem, Jackson Niyonzima, Nixon Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men |
title | Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men |
title_full | Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men |
title_fullStr | Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men |
title_full_unstemmed | Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men |
title_short | Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men |
title_sort | soluble programmed death-ligand 1 (spd-l1) is elevated in aggressive prostate cancer disease among african men |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098749/ https://www.ncbi.nlm.nih.gov/pubmed/35128628 http://dx.doi.org/10.1007/s40487-022-00184-6 |
work_keys_str_mv | AT katongolepaul solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT sandeobondoj solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT reynoldsstevenj solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT jolobamoses solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT kajumbulahenry solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT kalungisamuel solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT ssebambuliddekenneth solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT nakimulicynthia solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT atuheirwemaxine solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT oremjackson solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen AT niyonzimanixon solubleprogrammeddeathligand1spdl1iselevatedinaggressiveprostatecancerdiseaseamongafricanmen |